Monteplase

Drug Profile

Monteplase

Alternative Names: Cleactor; E 6010

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator ZymoGenetics
  • Developer Eisai; Eisai Co Ltd
  • Class Plasminogen activator enzymes; Thrombolytics
  • Mechanism of Action Plasminogen activators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Marketed Embolism; Myocardial infarction; Thrombosis
  • Discontinued Stroke

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 12 Oct 2010 ZymoGenetics has been acquired by Bristol-Myers Squibb
  • 02 Aug 2005 Launched for Embolism in Japan (Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top